Revolutionizing Neurology: Australian Consortium Unveils Quantum-Enabled “Brain-on-Chip” to Accelerate Drug Discovery
Tessara Therapeutics Ltd
A multinational partnership led by Tessara Therapeutics of Australia has announced the development of a novel quantum-enabled “Brain-on-Chip” technology, marking a paradigm leap for the pharmaceutical sector. By combining cutting-edge 3D human neural micro-tissues with quantum sensing, this technology seeks to close the long-standing gap between complex human clinical trials and laboratory cell cultures, providing new hope for the treatment of debilitating diseases like epilepsy, Parkinson’s disease, and Alzheimer’s.
You can also read 2025 International Year of Quantum Marks 100 Yrs of Discovery
Breaking the “Failure-Heavy” Cycle of Neuroscience
The discovery of drugs for neurological conditions has long been marked by high risk and an alarming failure rate. Because conventional preclinical models, particularly 2D cell cultures and animal models, are unable to reliably predict human biological responses, the majority of promising medicines fail during human trials. Animal models frequently fail to mimic certain human neurodegenerative diseases, even if 2D cultures lack the anatomical complexity of a living brain.
Tessara Therapeutics has developed a method called RealBrain that uses human induced pluripotent stem cells (iPSCs) to produce three-dimensional human neural micro-tissues. These micro-tissues are designed utilizing a patented synthetic hydrogel matrix that replicates the extracellular environment of the human brain, in contrast to basic cell clusters. As a result, neurons are able to self-organize into stable, functioning networks of neurons and glia, producing a “living” model that displays electrical signals that like those found in the human brain.
You can also read Quantinuum News: Advancing Large-Scale Logical Qubits
The Power of Quantum Diamond Sensing
The real breakthrough of the “Brain-on-Chip” platform is its capacity to “read” these three-dimensional tissues without causing harm to them. The consortium has incorporated a quantum sensing technique employing quantum diamond micropillar arrays through a collaboration with Chromos Labs.
Conventional techniques frequently use intrusive electrodes or hazardous fluorescent dyes to track brain activity. These diamond-based sensors, on the other hand, can image at high resolution without labels and are biocompatible. This “world-first high-aspect-ratio pillar fabrication” enables real-time detection of electrical signals at the millivolt scale from deep within 3D tissue.
The latest stage of development is concentrated on increasing the “field of view” of these sensors, according to Dr. Nikolai Dontschuk, Founder and CEO of Chromos Labs. “In this next phase, we are expanding the field of view so that we can measure the electrical signals across the whole RealBrain micro-tissues, ensuring we get the most comprehensive picture of the network state,” Dontschuk said.
You can also read Great Lakes Crystal Technologies Advancing Quantum Diamonds
Industrial Scale and Government Backing
Neurodegeneration is the platform’s primary clinical focus. Within three weeks, the Tessara Therapeutics ADBrain model can already replicate the telltale signs of Alzheimer’s disease, such as tau phosphorylation and amyloid buildup. This enables scientists to precisely assess the impact of a possible treatment on human brain networks prior to administering a dose to any patient.
The platform has been useful in testing neuroprotective medications such as NUZ-001 and Exenatide, in addition to Alzheimer’s disease. It was demonstrated by these investigations that the platform could measure not just cell survival but also the “connectivity” of the branching and network complexity of the neurons.
In the long run, the group hopes to use this technology to investigate mental health issues, including anxiety and schizophrenia. Researchers aim to produce “digital/biological twins” for tailored therapy using a patient’s own cells.
You can also read Connecticut Stock Outlook: $77.3M Surplus Economic Stability
A New Standard in Regulation
Scalability has been a major obstacle for “organ-on-chip” technology. Pharmaceutical companies can test thousands of drug candidates at once using this platform, which is built for high-throughput screening in 96-well and 384-well formats. By creating production routes that will make diamond chips as scalable and accessible as conventional computer hardware, Quantum Brilliance is significantly contributing to this area. Australia’s strengths in manufacturing and cutting-edge technology are combined in this consortium,” stated Dr. Marcus Doherty, Quantum Brilliance’s co-founder and chief technology officer. He underlined that the platform’s broad adoption depends on dependable, quantum-grade diamond.
A $2.1 million grant from the Critical Technologies Challenge Program (CTCP) of the Australian Government served as the impetus for the project. The goal of the $12.7 million initiative is to establish Australia as a leader in quantum biotechnology worldwide.
Industrial Scale and Government Backing
The FDA and other international regulators are starting to move away from requiring animal testing, which coincides with the development of the Brain-on-Chip technology. “The platform is in perfect alignment with this global regulatory shift toward more accurate, human-relevant methods,” said Dr. Christos Papadimitriou, CEO of Tessara Therapeutics.
The group wants to revolutionize biotech’s economics by collecting functional brain activity at scale. The objective is to transform neurology’s historically “failure-heavy” pipeline into a dependable, data-driven field.
Phase 1’s successful conclusion, which demonstrated that diamond sensors can see “below the surface” of neural tissues, is only the first step. This quantum-enabled technology might soon be a standard in labs across the globe as the consortium works toward a commercial prototype, radically altering the understanding of and approach to treating the human brain.
You can also read NASDAQ SEALSQ Launches Quantum-Resilient Security Stack
